ViralTherapeuticspre-clinical Deal with BI

This one's worth $350m or so and they have little clinical evidence to show for their work.  

Starting to wonder if we are missing out in this deal-doing activity somewhere...

http://www.viratherapeutics.com/app/download/5806089876/20160928_PR_BI ViraT_ENG_ViraT.pdf

"Boehringer Ingelheim is making a bid in oncolytic viruses in a deal with preclinical ViraTherapeutics that’s worth up to €210 million ($236 million). As part of the deal, the pharma gains the right to buy the biotech after Phase I development is finished."

"Congratulations to Prof. Dr. Dorothee von Laer and her team to this exciting collaboration and the pre-agreed option agreement to acquire the company. The potential transaction volume is absolutely meaningful and the possibility to jointly work with Boehringer Ingelheim on this innovative oncolytic virus therapy platform is a huge milestone for ViraTherapeutics and their supporters”, commented Dr. Klaus Schollmeier, Chairman of the ViraTherapeutics Board.